...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Pituitary Adenylate Cyclase-activating Polypeptides Prevent Hepatocyte Damage by Promoting Yes-associated Protein in Liver Ischemia-Reperfusion Injury
【24h】

Pituitary Adenylate Cyclase-activating Polypeptides Prevent Hepatocyte Damage by Promoting Yes-associated Protein in Liver Ischemia-Reperfusion Injury

机译:垂体腺苷酸环酶激活多肽通过在肝脏缺血再灌注损伤中促进Yes相关蛋白来防止肝细胞损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Hepatic ischemia-reperfusion injury (IRI) is a severe complication in liver transplantation, hepatectomy, and hemorrhagic shock. As neuropeptides transmit the regulatory signal between nervous and immune systems communication, our previous study documented that pituitary adenylate cyclase-activating polypeptides (PACAP) depressed hepatic Toll-like receptor 4 immune response in liver IRI. Methods. Here, we focused on how PACAP suppressed hepatocellular damage and enhanced hepatocyte regeneration in a murine model of partial liver warm IRI. Results. Yes-associated protein (YAP), a cellular modulator of tissue regeneration, was readily induced in wild type (WT) mouse IR-livers. As its induction was failed in PACAP-deficient livers, PACAP supplement enhanced YAP expression in WT mouse and promoted its nuclear translocation and downstream antioxidative/regenerative genes expression both in vivo and in vitro. Further, verteporfin, a YAP transcriptional inhibitor, abolished PACAP-mediated hepatoprotection significantly. Meanwhile, blockade of protein kinase A (PKA)-CRE-binding protein (CREB) signaling recreated liver damage in PACAP-protected liver as well as impeded stimulation on YAP and its downstream gene expressions. Consistently, inhibition of PKA-CREB decreased PACAP-promoted YAP expression in primary hepatocytes culture, and made them vulnerable to H2O2 stress in vitro. In addition, lysophosphatidic acid, another Hippo pathway inhibitor, failed to affect PACAP-mediated hepatoprotection or hepatocellular YAP induction. This implies that PACAP regulated YAP through PKA-CREB pathway at the transcriptional level rather than canonical hippo pathway. Conclusions. Our study discovered the neural modulation of PACAP-YAP axis in hepatic cytoprotection and homeostasis in liver IRI. These reveal a novel insight of neuropeptide PACAP in combating liver IRI in clinical patients.
机译:背景。肝缺血再灌注损伤(IRI)是肝移植,肝切除术和出血性休克的严重并发症。由于神经肽在神经和免疫系统通信之间传输调节信号,我们以前的研究记录了垂体腺苷酸环酶激活多肽(PACAP)抑郁的肝脏抑郁症的受体4免疫应答在肝脏IRI中。方法。在这里,我们专注于Pacap如何抑制肝细胞损伤和增强部分肝脏温暖IRI小鼠模型中的肝细胞再生。结果。是相关的蛋白质(YAP),组织再生的细胞调制剂,在野生型(WT)小鼠IR型肝脏中易于诱导。随着其诱导在PACAP缺陷型肝脏中失败,PACAP补充剂在WT小鼠中增强了YAP表达,并在体内和体外促进其核易位和下游抗氧化/再生基因表达。此外,Verteporfin,yap转录抑制剂,显着废除了PAPAP介导的肝保护。同时,阻断蛋白激酶A(PKA) - 克莱结合蛋白(CREB)信号传导在PACAP保护肝脏中重现肝脏损伤以及对YAP的受阻刺激及其下游基因表达。始终如一地,PKA-CREB对PKA-CREB的抑制降低了原发性肝细胞培养物中的PAPAP促进的yap表达,并使它们易于在体外易受H 2 O 2胁迫。此外,另一个河马途径抑制剂,溶血磷脂酸未能影响PACAP介导的肝或肝细胞yap诱导。这意味着PACAP通过在转录水平的PKA-CREB途径中调节YAP,而不是规范河马途径。结论。我们的研究发现了Pacap-Yap轴在肝脏IRI中的肝细胞保护和稳态的神经调节。这些揭示了神经肽Pacap在临床患者中对抗肝脏IRI的新颖洞察力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号